Pioglitazone Decreases Asymmetric Dimethylarginine Levels in Patients with Impaired Glucose Tolerance or Type 2 Diabetes

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies

(2013) M. Ferwana et al.   DIABETIC MEDICINE

Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression

(2012) Ayako Ojima et al.   AMERICAN JOURNAL OF PATHOLOGY

Asymmetrical dimethylarginine level is independently associated with circulating levels of RAGE and PEDF

(2012) Nobuhiro Tahara et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level

(2012) Yuji Ishibashi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus

(2011) Adrian V. Hernandez et al.   American Journal of Cardiovascular Drugs

Soluble Receptor of Advanced Glycated Endproducts Is Associated With Plaque Vulnerability in Patients With Acute Myocardial Infarction

(2011) Hun-Jun Park et al.   CIRCULATION JOURNAL

Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus

(2011) Ligia Petrica et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes

(2011) M. C. Thomas et al.   DIABETOLOGIA

Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy—Friend or foe?

(2011) Sho-ichi Yamagishi et al.   PHARMACOLOGICAL RESEARCH

The impact of pioglitazone on ADMA and oxidative stress markers in patients with type 2 diabetes

(2011) Dana E. King et al.   Primary Care Diabetes

Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation

(2010) Takanori Matsui et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis

(2010) Sayaka Maeda et al.   PHARMACOLOGICAL RESEARCH

Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?

(2009) N. Papanas et al.   CURRENT PHARMACEUTICAL DESIGN

Positive association of serum levels of advanced glycation end products and high mobility group box–1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients

(2009) Tsukasa Nakamura et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients

(2009) Ozen Oz Gul et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease

(2009) Sho-ichi Yamagishi et al.   PHARMACOLOGICAL RESEARCH

Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications

(2008) Sho-ichi Yamagishi et al.   CURRENT PHARMACEUTICAL DESIGN

Effect of Telmisartan on Nitric Oxide–Asymmetrical Dimethylarginine System

(2008) Fortunato Scalera et al.   HYPERTENSION

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

(2008) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION